For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. If you need to see your provider, please contact us to see if a Video Visit is right for you. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
Department of Anesthesiology

You are here

Publications

Author Title [ Type(Asc)] Year
Filters: Keyword is Atracurium  [Clear All Filters]
Journal Article
Savarese JJ, McGilvra JD, Sunaga H, Belmont MR, Van Ornum SG, Savard PM, Heerdt PM.  2010.  Rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011.. Anesthesiology. 113(1):58-73.
Lien CA, Schmith VD, Belmont MR, Abalos A, Kisor DF, Savarese JJ.  1996.  Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia.. Anesthesiology. 84(2):300-8.
deBros FM, Lai A, Scott R, deBros J, Batson AG, Goudsouzian N, Ali HH, Cosimi AB, Savarese JJ.  1986.  Pharmacokinetics and pharmacodynamics of atracurium during isoflurane anesthesia in normal and anephric patients.. Anesth Analg. 65(7):743-6.
Ornstein E, Lien CA, Matteo RS, Ostapkovich ND, Diaz J, Wolf KB.  1996.  Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients.. Anesthesiology. 84(3):520-5.
Savarese JJ.  1981.  The new neuromuscular blocking drugs are here.. Anesthesiology. 55(1):1-3.
Kopman AF, Klewicka MM, Kopman DJ, Neuman GG.  1999.  Molar potency is predictive of the speed of onset of neuromuscular block for agents of intermediate, short, and ultrashort duration.. Anesthesiology. 90(2):425-31.
Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR.  1996.  Importance of the organ-independent elimination of cisatracurium.. Anesth Analg. 83(5):1065-71.
Basta SJ, Savarese JJ, Ali HH, Moss J, Gionfriddo M.  1983.  Histamine-releasing potencies of atracurium, dimethyl tubocurarine and tubocurarine.. Br J Anaesth. 55 Suppl 1:105S-106S.
Sunaga H, Zhang Y, Savarese JJ, Emala CW.  2010.  Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs.. Anesthesiology. 112(4):892-9.
Savarese JJ, Wastila WB.  1995.  The future of the benzylisoquinolinium relaxants.. Acta Anaesthesiol Scand Suppl. 106:91-3.
Lien CA, Savard P, Belmont M, Sunaga H, Savarese JJ.  2009.  Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine.. J Crit Care. 24(1):50-7.
Ali HH, Savarese JJ, Basta SJ, Sunder N, Gionfriddo M.  1983.  Evaluation of cumulative properties of three new nondepolarizing neuromuscular blocking drugs BW A444U, atracurium and vecuronium.. Br J Anaesth. 55 Suppl 1:107S-111S.
Lien CA, Gadalla F, Kudlak TT, Embree PB, Sharp GJ, Savarese JJ.  1993.  The effect of ondansetron on atracurium-induced neuromuscular blockade.. J Clin Anesth. 5(5):399-403.
Suzuki T, Lien CA, Belmont MR, Tjan J, Savarese JJ.  2003.  Edrophonium effectively antagonizes neuromuscular block at the laryngeal adductors induced by rapacuronium, rocuronium and cisatracurium, but not mivacurium.. Can J Anaesth. 50(9):879-85.
Kopman AF, Lien CA, Naguib M.  2010.  Determining the potency of neuromuscular blockers: are traditional methods flawed? Br J Anaesth. 104(6):705-10.
Wastila WB, Maehr RB, Turner GL, Hill DA, Savarese JJ.  1996.  Comparative pharmacology of cisatracurium (51W89), atracurium, and five isomers in cats.. Anesthesiology. 85(1):169-77.
Diaz LL, Zhang J, Heerdt PM.  2014.  Comparative pharmacodynamics of pancuronium, cisatracurium, and CW002 in rabbits.. J Am Assoc Lab Anim Sci. 53(3):283-9.
Savarese JJ.  1986.  Clinical relaxation: current controversy.. Can Anaesth Soc J. 33(3 Pt 2):S1-4.
Savarese JJ, Lien CA, Belmont MR, Wastila WB.  1997.  [The clinical pharmacology of new benzylisoquinoline-diester compounds, with special consideration of cisatracurium and mivacurium].. Anaesthesist. 46(10):840-9.
Ali HH, Savarese JJ, Embree PB, Basta SJ, Stout RG, Bottros LH, Weakly JN.  1988.  Clinical pharmacology of mivacurium chloride (BW B1090U) infusion: comparison with vecuronium and atracurium.. Br J Anaesth. 61(5):541-6.
Scott RP, Savarese JJ, Basta SJ, Embree P, Ali HH, Sunder N, Hoaglin DC.  1986.  Clinical pharmacology of atracurium given in high dose.. Br J Anaesth. 58(8):834-8.
Basta SJ, Ali HH, Savarese JJ, Sunder N, Gionfriddo M, Cloutier G, Lineberry C, Cato AE.  1982.  Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant.. Anesth Analg. 61(9):723-9.
Belmont MR, Lien CA, Quessy S, Abou-Donia MM, Abalos A, Eppich L, Savarese JJ.  1995.  The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia.. Anesthesiology. 82(5):1139-45.
Lien CA, Belmont MR, Abalos A, Eppich L, Quessy S, Abou-Donia MM, Savarese JJ.  1995.  The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia.. Anesthesiology. 82(5):1131-8.
Scott RP, Savarese JJ, Basta SJ, Sunder N, Ali HH, Gargarian M, Gionfriddo M, Batson AG.  1985.  Atracurium: clinical strategies for preventing histamine release and attenuating the haemodynamic response.. Br J Anaesth. 57(6):550-3.